Mohamed F Doheim: Clarifying the Role of Late IV Thrombolysis in the Era of Endovascular Therapy
Mohamed F Doheim, Assistant Professor in Neurology (Clinical Research), NIH StrokeNet Fellow at the University of Pittsburgh School of Medicine, shared on LinkedIn about a recent article he and his colleagues co-authored, published in Neurology, adding:
”Excited to share my second publication in Neurology in a single day; this time on extended-window IV thrombolysis (IVT) for acute ischemic stroke (4.5–24 hours).
Across 18 RCTs and 5,168 patients, extended-window IVT improved excellent and good functional outcomes and reduced disability on the full mRS spectrum, with the expected increase in sICH but no excess mortality.
The central insight is why trial results have looked so heterogeneous.
Using multivariable meta-regression, we found that the main driver of between-study heterogeneity is whether patients also have access to endovascular thrombectomy (EVT).
Once EVT context is accounted for, much of the apparent variability in IVT effect becomes explainable.
Clinically, this means extended-window IVT may offer its greatest benefit in settings where thrombectomy is unavailable or delayed, especially for more severe strokes, positioning late IVT as a critical global reperfusion strategy rather than a niche protocol.
Proud to help clarify how IVT and EVT interact across trials and health systems, and to contribute evidence that can inform both guideline discussions and stroke systems of care worldwide.”
Title: Exploring Between-Study Heterogeneity in Extended-Window IV Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis of 18 Randomized Controlled Trials
Authors: Mohamed F. Doheim, Abdullah M. Al-Qudah, Romil Singh, Nirav R. Bhatt, Marcelo Rocha, Lawrence R. Wechsler, Gaoting Ma, Gisele Sampaio Silva, Sheila Co Martins, Chunrong Tao, Junwei Hao, Yamei Tang, Wei Hu, Lee H. Schwamm, Thanh N. Nguyen, Raul G. Nogueira
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI